134 related articles for article (PubMed ID: 36002752)
1. Intratumoral PD-1
Yu K; Gu Y; Zhang P; Fang H; Cao Y; Wang J; Lin C; Liu H; Zhang H; He H; Li R; Qin J; Li H; Xu J
Br J Cancer; 2022 Nov; 127(9):1709-1717. PubMed ID: 36002752
[TBL] [Abstract][Full Text] [Related]
2. Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.
Liu X; Cao Y; Li R; Gu Y; Chen Y; Qi Y; Lv K; Wang J; Yu K; Lin C; Liu H; Zhang H; He H; Chen L; Zhang P; Shen Z; Qin J; Sun Y; Li H; Huang H; Zhang W; Xu J
Eur J Cancer; 2020 Mar; 128():27-37. PubMed ID: 32109848
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
4. Impact of intratumoural CD96 expression on clinical outcome and therapeutic benefit in gastric cancer.
Xu C; Fang H; Gu Y; Yu K; Wang J; Lin C; Zhang H; Li H; He H; Liu H; Li R
Cancer Sci; 2022 Dec; 113(12):4070-4081. PubMed ID: 35997524
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating podoplanin
Liu X; Cao Y; Lv K; Gu Y; Jin K; He X; Fang H; Fei Y; Shi M; Lin C; Liu H; Li H; He H; Xu J; Li R; Zhang H
Oncoimmunology; 2020 Nov; 9(1):1845038. PubMed ID: 33235820
[TBL] [Abstract][Full Text] [Related]
6. Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer.
Xia S; Gu Y; Zhang H; Fei Y; Cao Y; Fang H; Wang J; Lin C; Zhang H; Li H; He H; Xu J; Li R; Liu H; Zhang W
Oncoimmunology; 2021; 10(1):1975386. PubMed ID: 34552824
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral Foxp3
Fei Y; Cao Y; Gu Y; Fang H; Chen Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2022 Jan; 71(1):1-11. PubMed ID: 33978826
[TBL] [Abstract][Full Text] [Related]
9. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.
Linedale R; Schmidt C; King BT; Ganko AG; Simpson F; Panizza BJ; Leggatt GR
PLoS One; 2017; 12(4):e0175755. PubMed ID: 28423034
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigen-specific CD8
Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
[TBL] [Abstract][Full Text] [Related]
11. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
12. Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients.
Jin K; Cao Y; Gu Y; Fang H; Fei Y; Wang J; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Li R; Zhang H; Xu J
Oncoimmunology; 2021 Apr; 10(1):1915560. PubMed ID: 33996266
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression.
Pereira MA; de Castria TB; Ramos MFKP; Dias AR; Cardili L; de Moraes RDR; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES
J Surg Oncol; 2021 Dec; 124(7):1040-1050. PubMed ID: 34255356
[TBL] [Abstract][Full Text] [Related]
14. TIM3
Chen K; Gu Y; Cao Y; Fang H; Lv K; Liu X; He X; Wang J; Lin C; Liu H; Zhang H; He H; Xu J; Li H; Li R
Br J Cancer; 2022 Jan; 126(1):100-108. PubMed ID: 34725458
[TBL] [Abstract][Full Text] [Related]
15. TIGIT and PD-1 may serve as potential prognostic biomarkers for gastric cancer.
Xu D; Zhao E; Zhu C; Zhao W; Wang C; Zhang Z; Zhao G
Immunobiology; 2020 May; 225(3):151915. PubMed ID: 32122675
[TBL] [Abstract][Full Text] [Related]
16. Increased exhausted CD8
Tan J; Chen S; Huang J; Chen Y; Yang L; Wang C; Zhong J; Lu Y; Wang L; Zhu K; Li Y
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e266-e274. PubMed ID: 29943497
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating CD226
Zhang Y; Zhao ZX; Gao JP; Huang YK; Huang H
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4381-4389. PubMed ID: 36107244
[TBL] [Abstract][Full Text] [Related]
18. Intratumoral CD103
Gu Y; Chen Y; Jin K; Cao Y; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Qin J; Li R; Zhang H; Zhang W
Oncoimmunology; 2020 Nov; 9(1):1844402. PubMed ID: 33312758
[TBL] [Abstract][Full Text] [Related]
19. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
20. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
